| HOME >> BIOLOGY >> TECHNOLOGY |
Angiotech is offering to pay $165 million (including accrued and unpaid interest and the Early Tender Premiums) for all Notes purchased. The amounts of each series of Notes that are purchased in the tender offer will be determined in accordance with the "Acceptance Priority Level" described in the Offer to Purchase. All Senior Floating Rate Notes due 2013 (the "First Priority Notes") will be accepted before any 7.75% Subordinated Notes due 2014 (the "Second Priority Notes") are accepted. The tender is conditioned upon, among other things, (a) the tender of an amount of First Priority Notes that will result in a purchase price (including accrued and unpaid interest and the Early Tender Premiums) for the First Priority Notes of at least $85.8 million and (b) the tender of an amount of all Notes that will result in a purchase price equal to $165 million (including accrued and unpaid interest and the Early Tender Premiums) (collectively, the "Minimum Tender Condition"). The tender of Second Priority Notes is limited to an amount of Second Priority Notes that will not result in a purchase price (including accrued and unpaid interest and the Early Tender Premiums) for the Second Priority Notes that exceeds $79.2 million.
In addition to the Acceptance Priority Level and minimum and maximum
amounts described above, depending on the amount of Notes tendered, the
amount of Notes accepted for purchase from each holder tendering may be
subject to proration
'/>"/>
| SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |